Financials data is unavailable for this security.
View more
Year on year OptimizeRx Corp 's net income fell 53.57% from a loss of 11.44m to a larger loss of 17.57m despite revenues that grew 14.53% from 62.45m to 71.52m. An increase in the cost of goods sold as a percentage of sales from 37.60% to 40.02% was a component in the falling net income despite rising revenues.
| Gross margin | 61.96% |
|---|---|
| Net profit margin | -21.53% |
| Operating margin | -27.93% |
| Return on assets | -12.18% |
|---|---|
| Return on equity | -15.13% |
| Return on investment | -13.09% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at OptimizeRx Corp fell by 4.36m. Cash Flow from Financing totalled 28.22m or 39.46% of revenues. In addition the company used 7.24m for operations while cash used for investing totalled 25.34m.
| Cash flow per share | -0.8075 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.61 |
|---|---|
| Tangible book value per share | -0.2628 |
More ▼
Balance sheet in USDView more
| Current ratio | 3.07 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.2941 |
|---|---|
| Total debt/total capital | 0.2273 |
More ▼
